PR Newswire
SALT LAKE CITY, March 21, 2019
SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic
potential for non-alcoholic steatohepatitis ("NASH") at the ROTH Battle of the NASH Thrones Spring Investor Conference, being
held March 28, 2019 in New York City.
|
ROTH Battle of the NASH Thrones Spring Investor Conference
|
|
Date:
|
Thursday, March 28th
|
|
Location:
|
Park Hyatt New York, Onyx Room
|
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products to treat metabolic and
endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four
development programs TLANDO, LPCN 1144, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing
testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1144, an oral prodrug
of bioidentical testosterone, is being developed as a treatment of non-alcoholic steatohepatitis ("NASH") and recently completed
a proof-of-concept clinical study demonstrating substantial liver fat reductions in hypogonadal males assessed using magnetic
resonance imaging, proton density fat fraction ("MRI-PDFF") technique. LPCN 1111, a novel oral prodrug of
testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for
once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate
product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the
FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-to-participate-at-the-roth-battle-of-the-nash-thrones-spring-investor-conference-300815930.html
SOURCE Lipocine Inc.
